[{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Oxalate","graph1":"Nephrology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nephrology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ DCVC Bio"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Genetically Engineered Microbial Medicines","moa":"","graph1":"Gastroenterology","graph2":"Discovery","graph3":"Novome Biotechnologies","amount2":0.60999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0.60999999999999999,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Novome Biotechnologies \/ Genentech","highestDevelopmentStatusID":"2","companyTruncated":"Novome Biotechnologies \/ Genentech"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"NB1000S","moa":"","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Novome Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Novome Biotechnologies","sponsor":"Tencent","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2022","type":"Series B Financing","leadProduct":"NB1000S","moa":"Oxalate","graph1":"Gastroenterology","graph2":"Phase I\/ Phase II","graph3":"Novome Biotechnologies","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Novome Biotechnologies \/ Tencent","highestDevelopmentStatusID":"7","companyTruncated":"Novome Biotechnologies \/ Tencent"}]

Find Clinical Drug Pipeline Developments & Deals by Novome Biotechnologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The proceeds will be used to advance both Novome’s clinical hyperoxaluria candidate, NOV001, through an ongoing Phase 2a clinical trial and multiple Genetically Engineered Microbial Medicines (GEMMs) candidates for the potential treatment of inflammato...

                          Brand Name : NOV-001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 13, 2022

                          Lead Product(s) : NB1000S,NB2000P

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Tencent

                          Deal Size : $43.5 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : NOV-001 is an investigational combination product composed of NB1000S and NB2000P. Preclinical studies of NOV001 showed consistent and robust reduction in urine oxalate levels in multiple animal models of disease.

                          Brand Name : NOV-001

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 17, 2021

                          Lead Product(s) : NB1000S,NB2000P

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the agreement, Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : $15.0 million

                          November 10, 2021

                          Lead Product(s) : Genetically Engineered Microbial Medicines

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Discovery

                          Sponsor : Genentech

                          Deal Size : $605.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 07, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Nephrology

                          Highest Development Status : Discovery

                          Sponsor : DCVC Bio

                          Deal Size : $33.0 million

                          Deal Type : Series A Financing

                          blank